By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
| Currency | US Dollars |
| Share Price | $ 186.91 |
| Change Today | $ 4.30 |
| % Change | 2.35 % |
| 52 Week High | $187.06 |
| 52 Week Low | $118.84 |
| Volume | 3 |
| Shares Issued | 145.80m |
| Market Cap | $27,252m |
| RiskGrade | 259 |
| Strong Buy | 8 |
| Buy | 6 |
| Neutral | 19 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 34 |

You are here: research